Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company focused on developing ready-to-use, precision T cell therapies. Their research and development efforts span virology, oncology, and neurological conditions. The company's flagship experimental treatment, TVGN 489, is a precision T cell product designed to meet the unmet needs of individuals severely affected by acute COVID-19, as well as a specific group of patients struggling with long COVID. Tevogen Bio Holdings Inc. is headquartered in Warren, New Jersey.
Target Price
The average target price of TVGN is 5.00 and suggests 26.1% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to d